Article ; Online: Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature.
2021 Volume 186, Issue 2, Page(s) 289–298
Abstract: ... review of the literature and identified seven additional cases of COVID-19 associated mucormycosis (CAM). Of the eight ... mucormycosis in a 55-year-old man with diabetes, end-stage kidney disease, and COVID-19. The index case was ... Severe coronavirus disease (COVID-19) is currently managed with systemic glucocorticoids ...
| Abstract | Severe coronavirus disease (COVID-19) is currently managed with systemic glucocorticoids. Opportunistic fungal infections are of concern in such patients. While COVID-19 associated pulmonary aspergillosis is increasingly recognized, mucormycosis is rare. We describe a case of probable pulmonary mucormycosis in a 55-year-old man with diabetes, end-stage kidney disease, and COVID-19. The index case was diagnosed with pulmonary mucormycosis 21 days following admission for severe COVID-19. He received 5 g of liposomal amphotericin B and was discharged after 54 days from the hospital. We also performed a systematic review of the literature and identified seven additional cases of COVID-19 associated mucormycosis (CAM). Of the eight cases included in our review, diabetes mellitus was the most common risk factor. Three subjects had no risk factor other than glucocorticoids for COVID-19. Mucormycosis usually developed 10-14 days after hospitalization. All except the index case died. In two subjects, CAM was diagnosed postmortem. Mucormycosis is an uncommon but serious infection that complicates the course of severe COVID-19. Subjects with diabetes mellitus and multiple risk factors may be at a higher risk for developing mucormycosis. Concurrent glucocorticoid therapy probably heightens the risk of mucormycosis. A high index of suspicion and aggressive management is required to improve outcomes. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Adenosine Monophosphate/analogs & derivatives ; Adenosine Monophosphate/therapeutic use ; Alanine/analogs & derivatives ; Alanine/therapeutic use ; Antiviral Agents/therapeutic use ; COVID-19/complications ; COVID-19/therapy ; Diabetes Complications ; Glucocorticoids/therapeutic use ; Humans ; Kidney Failure, Chronic/complications ; Kidney Failure, Chronic/therapy ; Male ; Middle Aged ; Mucormycosis/complications ; Mucormycosis/microbiology ; Mucormycosis/therapy ; Rhizopus/isolation & purification ; Risk Factors ; Tomography, X-Ray Computed ; Treatment Outcome | |||||
| Chemical Substances | Antiviral Agents ; Glucocorticoids ; remdesivir (3QKI37EEHE) ; Adenosine Monophosphate (415SHH325A) ; Alanine (OF5P57N2ZX) | |||||
| Language | English | |||||
| Publishing date | 2021-02-05 | |||||
| Publishing country | Netherlands | |||||
| Document type | Case Reports ; Journal Article ; Systematic Review | |||||
| ZDB-ID | 391081-7 | |||||
| ISSN | 1573-0832 ; 0369-299X ; 0301-486X ; 0027-5530 | |||||
| ISSN (online) | 1573-0832 | |||||
| ISSN | 0369-299X ; 0301-486X ; 0027-5530 | |||||
| DOI | 10.1007/s11046-021-00528-2 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Ud II Zs.99: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.